David R Snydman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7238003/publications.pdf

Version: 2024-02-01

256 papers

18,677 citations

¹⁶⁷⁹¹ 66 h-index 130 g-index

261 all docs

261 does citations

261 times ranked

14674 citing authors

#	Article	IF	CITATIONS
1	<i>Clostridioides difficile</i> infection in solid organ and hematopoietic stem cell transplant recipients: A prospective multinational study. Transplant Infectious Disease, 2022, 24, e13770.	0.7	3
2	Association Between Lymphopenia at 1 Month Posttransplant and Infectious Outcomes or Death in Heart Transplant Recipients. Clinical Infectious Diseases, 2021, 73, e3797-e3803.	2.9	7
3	Antiviral treatment approaches for cytomegalovirus prevention in kidney transplant recipients: A systematic review of randomized controlled trials. Transplantation Reviews, 2021, 35, 100587.	1.2	2
4	Epidemiology, risk factors, and outcomes associated with cytomegalovirus in adult kidney transplant recipients: A systematic literature review of realâ€world evidence. Transplant Infectious Disease, 2021, 23, e13483.	0.7	31
5	Factors associated with neutropenia post heart transplantation. Transplant Infectious Disease, 2021, 23, e13634.	0.7	5
6	Difference in absolute lymphocyte count among male and female heart transplant recipients. Clinical Transplantation, 2021, 35, e14412.	0.8	1
7	937. A Clinical Prediction Tool to Determine Risk of Infection in the First Year Following Heart Transplant. Open Forum Infectious Diseases, 2021, 8, S560-S561.	0.4	0
8	<i>In Vitro</i> Evaluation of the Activity of Aztreonam-Avibactam against 341 Recent Clinical Isolates of Anaerobes. Microbiology Spectrum, 2021, 9, e0190821.	1.2	0
9	Ridinilazole, a narrow spectrum antibiotic for treatment of <i>Clostridioides difficile</i> infection, enhances preservation of microbiota-dependent bile acids. American Journal of Physiology - Renal Physiology, 2020, 319, G227-G237.	1.6	29
10	The Impact of Enhanced Antimicrobial Stewardship Support on Antibiotic Starts in Long-Term Care Facilities. Infection Control and Hospital Epidemiology, 2020, 41, s527-s527.	1.0	0
11	1706. Association between <i>Cytomegalovirus</i> Infection/Disease and Morbidity and Mortality in Kidney Transplantation: A Systematic Literature Review of Observational Studies. Open Forum Infectious Diseases, 2020, 7, S835-S836.	0.4	0
12	The effect of respiratory viral assay panel on antibiotic prescription patterns at discharge in adults admitted with mild to moderate acute exacerbation of COPD: a retrospective before- after study. BMC Pulmonary Medicine, 2019, 19, 118.	0.8	5
13	The impact of recurrent cytomegalovirus infection on longâ€ŧerm survival in solid organ transplant recipients. Transplant Infectious Disease, 2019, 21, e13189.	0.7	13
14	Impact of Body Mass Index (BMI) on the Effect of a Lactobacillus Rhamnosus GG (LGG)/Bifidobacterium Animalis Subspecies Lactis BB-12 (BB-12) Combination on Gut Microbiota (P20-023-19). Current Developments in Nutrition, 2019, 3, nzz040.P20-023-19.	0.1	0
15	Reactivation of latent cytomegalovirus infection in patients with rheumatologic disease: a case–control study. Rheumatology International, 2019, 39, 1229-1240.	1.5	15
16	U.SBased National Surveillance for Fidaxomicin Susceptibility of Clostridioides difficile-Associated Diarrheal Isolates from 2013 to 2016. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	30
17	Potential mortality benefit from secondary prophylaxis following CMV treatment completion may be due to confounding by transplant organ type. Transplant Infectious Disease, 2019, 21, e13051.	0.7	2
18	Diagnosis and management of diarrhea in solidâ€organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clinical Transplantation, 2019, 33, e13550.	0.8	45

#	Article	IF	CITATIONS
19	Reactivation of Latent Cytomegalovirus Infection after Major Surgery: Risk Factors and Outcomes. Surgical Infections, 2019, 20, 416-423.	0.7	6
20	Correlation of Cytomegalovirus (CMV) Disease Severity and Mortality With CMV Viral Burden in CMV-Seropositive Donor and CMV-Seronegative Solid Organ Transplant Recipients. Open Forum Infectious Diseases, 2019, 6, ofz003.	0.4	36
21	2567. Effect of Broad vs. Narrow-Spectrum Clostridioides difficile Treatment on Human Stool Bile Acid Composition Over Time. Open Forum Infectious Diseases, 2019, 6, S891-S891.	0.4	O
22	2578. Narrow-Spectrum Antibiotic Treatment of Clostridium difficile Infection Improves Preservation of Intestinal Metabolic Profile. Open Forum Infectious Diseases, 2019, 6, S896-S896.	0.4	0
23	2670. Clostridioides difficile Infection (CDI) in Solid-Organ (SOT) and Hematopoietic Stem Cell Transplant (HCT) Recipients: A Prospective Multinational Study. Open Forum Infectious Diseases, 2019, 6, S936-S936.	0.4	0
24	Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study. Multiple Sclerosis Journal, 2019, 25, 1605-1617.	1.4	57
25	Evaluation of the In Vitro Activity of Eravacycline against a Broad Spectrum of Recent Clinical Anaerobic Isolates. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	35
26	A repeat offender: Recurrent extraintestinal Clostridium difficile infection following fecal microbiota transplantation. Anaerobe, 2018, 51, 68-72.	1.0	7
27	Absolute Lymphocyte Count: A Predictor of Recurrent Cytomegalovirus Disease in Solid Organ Transplant Recipients. Clinical Infectious Diseases, 2018, 67, 1395-1402.	2.9	57
28	Antimicrobial susceptibility and ribotypes of Clostridium difficile isolates from a Phase 2 clinical trial of ridinilazole (SMT19969) and vancomycin. Journal of Antimicrobial Chemotherapy, 2018, 73, 2078-2084.	1.3	15
29	Evaluation of a two-stage testing algorithm for the diagnosis of respiratory viral infections. Diagnostic Microbiology and Infectious Disease, 2018, 91, 319-323.	0.8	3
30	1537. Reactivation of Latent Cytomegalovirus Infection in Patients with Rheumatologic Disease: A Case–Control Study. Open Forum Infectious Diseases, 2018, 5, S477-S477.	0.4	0
31	672. The Impact on Humans of Treating Dogs with Amoxicillin/Clavulanate. Open Forum Infectious Diseases, 2018, 5, S243-S243.	0.4	0
32	1510. Treatment of Asymptomatic Bacteriuria prior to Transcatheter Aortic Valve Replacement. Open Forum Infectious Diseases, 2018, 5, S467-S467.	0.4	0
33	1774. Ridinilazole (RDZ) for Clostridium difficile infection (CDI): Correlation of In Vitro Spectrum of Activity with Human Gut Microbiome Profiles from a Phase 2 Clinical Trial. Open Forum Infectious Diseases, 2018, 5, S67-S67.	0.4	0
34	1551. The Impact of Recurrent CMV Disease on Long-Term Survival in Solid Organ Transplant Recipients. Open Forum Infectious Diseases, 2018, 5, S481-S482.	0.4	1
35	2506. Reactivation of Latent Cytomegalovirus Infection Following Major Surgery: Risk Factors and Outcomes. Open Forum Infectious Diseases, 2018, 5, S753-S753.	0.4	0
36	Microbial Identification Using DNA Target Amplification and Sequencing: Clinical Utility and Impact on Patient Management. Open Forum Infectious Diseases, 2018, 5, ofy257.	0.4	14

3

#	Article	IF	CITATIONS
37	Enhanced preservation of the human intestinal microbiota by ridinilazole, a novel Clostridium difficile-targeting antibacterial, compared to vancomycin. PLoS ONE, 2018, 13, e0199810.	1.1	44
38	Selective method for identification and quantification of <i>Bifidobacterium animalis </i> subspecies <i>lactis </i> BB-12 (BB-12) from the gastrointestinal tract of healthy volunteers ingesting a combination probiotic of BB-12 and <i>Lactobacillus rhamnosus </i> GG. Journal of Applied Microbiology, 2017, 122, 1321-1332.	1.4	10
39	Evaluation of the Clinical Impact of the Biofire Filmarray® Rapid Multiplex PCR Assay in Blood Culture Identification Combined with Antimicrobial Stewardship Intervention. Open Forum Infectious Diseases, 2017, 4, S627-S627.	0.4	0
40	Role of Secondary Prophylaxis with Valganciclovir in the Prevention of Recurrent Cytomegalovirus Disease in Solid Organ Transplant Recipients. Open Forum Infectious Diseases, 2017, 4, S712-S712.	0.4	0
41	Ironâ€related markers are associated with infection after liver transplantation. Liver Transplantation, 2017, 23, 1541-1552.	1.3	10
42	Role of Secondary Prophylaxis With Valganciclovir in the Prevention of Recurrent Cytomegalovirus Disease in Solid Organ Transplant Recipients. Clinical Infectious Diseases, 2017, 65, 2000-2007.	2.9	41
43	Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation. New England Journal of Medicine, 2017, 377, 2433-2444.	13.9	796
44	Trends in antimicrobial resistance among Bacteroides species and Parabacteroides species in the United States from 2010–2012 with comparison to 2008–2009. Anaerobe, 2017, 43, 21-26.	1.0	56
45	Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of RG7667, a Combination Monoclonal Antibody, for Prevention of Cytomegalovirus Infection in High-Risk Kidney Transplant Recipients. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	70
46	Epidemiologic Trends in Clostridium difficile Isolate Ribotypes in United States from 2010 to 2014. Open Forum Infectious Diseases, 2017, 4, S391-S391.	0.4	4
47	Clinical Utility of Universal PCR and its Real-world Impact on Patient Management. Open Forum Infectious Diseases, 2017, 4, S627-S627.	0.4	2
48	Outcomes of Clostridium difficile Infection by Diagnostic Test in Inflammatory Bowel Disease. American Journal of Gastroenterology, 2017, 112, S360.	0.2	0
49	Characteristics and outcomes of neutropenia after orthotopic liver transplantation. Liver Transplantation, 2016, 22, 217-225.	1.3	22
50	Increasing Infectious Endocarditis Admissions Among Young People Who Inject Drugs. Open Forum Infectious Diseases, 2016, 3, ofw157.	0.4	292
51	<i>In Vitro</i> Evaluation of the Activity of Imipenem-Relebactam against 451 Recent Clinical Isolates of Bacteroides Group and Related Species. Antimicrobial Agents and Chemotherapy, 2016, 60, 6393-6397.	1.4	21
52	Risks and Epidemiology of Infections Associated with Ventricular Assist Devices and Heart Transplantation. , 2016 , , $151\text{-}165$.		0
53	Differences in the Molecular Epidemiology and Antibiotic Susceptibility of Clostridium difficile Isolates in Pediatric and Adult Patients. Antimicrobial Agents and Chemotherapy, 2016, 60, 4896-4900.	1.4	21
54	<i>Editorial Commentary</i> : Chronic Lung Allograft Dysfunction in Lung Transplant Recipients: Another Piece of the Puzzle. Clinical Infectious Diseases, 2016, 62, 320-322.	2.9	5

#	Article	IF	CITATIONS
55	In vitro evaluation of cytomegalovirusâ€specific hyperimmune globulins vs. standard intravenous immunoglobulins. Vox Sanguinis, 2015, 109, 71-78.	0.7	19
56	Physician report cards and rankings yield long-lasting hand hygiene compliance exceeding 90Â%. Critical Care, 2015, 19, 292.	2.5	16
57	Effect of Lactobacillus rhamnosus GG Administration on Vancomycin-Resistant Enterococcus Colonization in Adults with Comorbidities. Antimicrobial Agents and Chemotherapy, 2015, 59, 4593-4599.	1.4	41
58	Economic Consequences of Cytomegalovirus Disease Among Stem Cell Transplant Recipients. Biology of Blood and Marrow Transplantation, 2015, 21, S296.	2.0	3
59	A national survey of infectious disease practitioners on their use of outpatient parenteral antimicrobial therapy (OPAT). Infectious Diseases, 2015, 47, 39-45.	1.4	39
60	Risk and Safety of Probiotics. Clinical Infectious Diseases, 2015, 60, S129-S134.	2.9	606
61	U.SBased National Sentinel Surveillance Study for the Epidemiology of Clostridium difficile-Associated Diarrheal Isolates and Their Susceptibility to Fidaxomicin. Antimicrobial Agents and Chemotherapy, 2015, 59, 6437-6443.	1.4	58
62	1681Randomized Clinical Trial of the Recovery of Probiotics Lactobacillus rhamnosus GG (LGG) and Bifidobacterium animalis subspecies lactis (BB-12) from the Gastrointestinal (GI) Tract of Healthy Volunteers. Open Forum Infectious Diseases, 2014, 1, S449-S449.	0.4	0
63	Activity of Ceftolozane-Tazobactam against a Broad Spectrum of Recent Clinical Anaerobic Isolates. Antimicrobial Agents and Chemotherapy, 2014, 58, 1218-1223.	1.4	37
64	Horizontal Infection Control Strategy Decreases Methicillin-Resistant Staphylococcus aureus Infection and Eliminates Bacteremia in a Surgical ICU Without Active Surveillance*. Critical Care Medicine, 2014, 42, 2151-2157.	0.4	12
65	The Efficacy of Daptomycin Versus Vancomycin for Methicillin-Resistant Staphylococcus aureus Bloodstream Infection in Patients With Impaired Renal Function. Clinical Infectious Diseases, 2014, 58, 1533-1539.	2.9	15
66	Prediction Model for 30-Day Hospital Readmissions Among Patients Discharged Receiving Outpatient Parenteral Antibiotic Therapy. Clinical Infectious Diseases, 2014, 58, 812-819.	2.9	99
67	Editorial Commentary: The Complexity of Latent Cytomegalovirus Infection in Stem Cell Donors. Clinical Infectious Diseases, 2014, 59, 482-483.	2.9	3
68	Pretransplant Lymphopenia is a Novel Prognostic Factor in CMV and Non-CMV Invasive Infection After Liver Transplantation. Liver Transplantation, 2014, 20, n/a-n/a.	1.3	25
69	No Evidence of Harms of Probiotic Lactobacillus rhamnosus GG ATCC 53103 in Healthy Elderly—A Phase I Open Label Study to Assess Safety, Tolerability and Cytokine Responses. PLoS ONE, 2014, 9, e113456.	1.1	39
70	Carbapenem-resistant enterobacteriaceae: analyzing knowledge and practice in healthcare providers. PeerJ, 2014, 2, e405.	0.9	4
71	Vancomycin-Resistant Enterococcus Infections in Solid Organ Transplantation. American Journal of Transplantation, 2013, 13, 59-67.	2.6	33
72	The impact of cefepime as first line therapy for neutropenic fever on Clostridium difficile rates among hematology and oncology patients. Anaerobe, 2013, 24, 79-81.	1.0	19

#	Article	IF	Citations
73	A Nationwide Survey of Antimicrobial Stewardship Practices. Clinical Therapeutics, 2013, 35, 758-765.e20.	1.1	65
74	Outpatient parenteral antimicrobial therapy (OPAT) in the republic of Ireland: results of a national survey. European Journal of Clinical Microbiology and Infectious Diseases, 2013, 32, 1465-1470.	1.3	18
75	Are We Ready for an Outpatient Parenteral Antimicrobial Therapy Bundle? A Critical Appraisal of the Evidence. Clinical Infectious Diseases, 2013, 57, 419-424.	2.9	57
76	778. Critical Care Medicine, 2013, 41, A193-A194.	0.4	0
77	Activity of a Novel Cyclic Lipopeptide, CB-183,315, against Resistant Clostridium difficile and Other Gram-Positive Aerobic and Anaerobic Intestinal Pathogens. Antimicrobial Agents and Chemotherapy, 2012, 56, 3448-3452.	1.4	50
78	Nosocomial Hepatitis C: More of a Hidden Epidemic. Annals of Internal Medicine, 2012, 156, 534.	2.0	4
79	Carbapenem-Resistant Enterobacteriaceae: A Statewide Survey of Detection in Massachusetts Hospitals. Infection Control and Hospital Epidemiology, 2012, 33, 954-956.	1.0	8
80	First report of a left ventricular assist device infection caused by Staphylococcus schleiferi subspecies coagulans: a coagulase-positive organism. Diagnostic Microbiology and Infectious Disease, 2012, 74, 68-69.	0.8	18
81	Empiric antibiotic selection strategies for healthcare-associated pneumonia, intra-abdominal infections, and catheter-associated bacteremia. Journal of Hospital Medicine, 2012, 7, S2-S12.	0.7	13
82	High Incidence of Herpes Zoster in Nonmyeloablative Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2011, 17, 1012-1017.	2.0	33
83	Why did maribavir fail in stem-cell transplants?. Lancet Infectious Diseases, The, 2011, 11, 255-257.	4.6	16
84	A Multifaceted Approach to Education, Observation, and Feedback in a Successful Hand Hygiene Campaign. Joint Commission Journal on Quality and Patient Safety, 2011, 37, 3-AP3.	0.4	40
85	The impact of CMV prevention on longâ€term recipient and graft survival in heart transplant recipients: analysis of the Scientific Registry of Transplant Recipients (SRTR) database. Clinical Transplantation, 2011, 25, E455-62.	0.8	26
86	Lactobacillus GG as an immune adjuvant for live-attenuated influenza vaccine in healthy adults: a randomized double-blind placebo-controlled trial. European Journal of Clinical Nutrition, 2011, 65, 501-507.	1.3	148
87	Putting the IMPACT Study into Perspective: Should CMV Prophylaxis Be Extended to 6 Months for High Risk Transplants?. American Journal of Transplantation, 2011, 11, 6-7.	2.6	4
88	Update and Review: State-of-the-Art Management of Cytomegalovirus Infection and Disease Following Thoracic Organ Transplantation. Transplantation Proceedings, 2011, 43, S1-S17.	0.3	83
89	Update on resistance of Bacteroides fragilis group and related species with special attention to carbapenems 2006–2009. Anaerobe, 2011, 17, 147-151.	1.0	101
90	Persistent babesiosis in a stem cell transplant recipient. Leukemia Research, 2011, 35, e77-e78.	0.4	24

#	Article	IF	Citations
91	Predicting High Vancomycin Minimum Inhibitory Concentration in Methicillin-Resistant Staphylococcus aureus Bloodstream Infections. Clinical Infectious Diseases, 2011, 52, 997-1002.	2.9	30
92	<i>In Vitro</i> Activity of Ceftaroline against a Broad Spectrum of Recent Clinical Anaerobic Isolates. Antimicrobial Agents and Chemotherapy, 2011, 55, 421-425.	1.4	24
93	Reply to van Hal et al. Clinical Infectious Diseases, 2011, 53, 1167-1168.	2.9	0
94	Blood stream infection (BSI) and acute GVHD after hematopoietic SCT (HSCT) are associated. Bone Marrow Transplantation, 2011, 46, 300-307.	1.3	80
95	A randomized, double-blind, placebo-controlled trial of valacyclovir prophylaxis to prevent zoster recurrence from months 4 to 24 after BMT. Bone Marrow Transplantation, 2011, 46, 294-299.	1.3	31
96	International Consensus Guidelines on the Management of Cytomegalovirus in Solid Organ Transplantation. Transplantation, 2010, 89, 779-795.	0.5	898
97	Cytomegalovirus Prevention and Long-Term Recipient and Graft Survival in Pediatric Heart Transplant Recipients. Transplantation, 2010, 90, 1432-1438.	0.5	22
98	Leflunomide: A Small Step Forward in Meeting the Urgent Need for Treatment of Drug-Resistant Cytomegalovirus Infection. Transplantation, 2010, 90, 362-363.	0.5	11
99	Evaluation of Vancomycin and Daptomycin Potency Trends (MIC Creep) against Methicillin-Resistant <i>Staphylococcus aureus (i> Isolates Collected in Nine U.S. Medical Centers from 2002 to 2006. Antimicrobial Agents and Chemotherapy, 2010, 54, 1383-1383.</i>	1.4	6
100	Increased Serum Iron Levels and Infectious Complications after Liver Transplantation. Clinical Infectious Diseases, 2010, 51, e16-e23.	2.9	31
101	Lessons Learned from the Anaerobe Survey: Historical Perspective and Review of the Most Recent Data (2005–2007). Clinical Infectious Diseases, 2010, 50, S26-S33.	2.9	139
102	Evaluation of Vancomycin and Daptomycin Potency Trends (MIC Creep) against Methicillin-Resistant <i>Staphylococcus aureus </i> Isolates Collected in Nine U.S. Medical Centers from 2002 to 2006. Antimicrobial Agents and Chemotherapy, 2009, 53, 4127-4132.	1.4	113
103	Cytomegalovirus Prevention Strategies: The Case for Prophylaxis. American Journal of Transplantation, 2009, 9, 1254-1254.	2.6	2
104	Cytomegalovirus in Solid Organ Transplant Recipients. American Journal of Transplantation, 2009, 9, S78-S86.	2.6	289
105	Severity of illness scoring systems in patients with bacteraemic pneumococcal pneumonia: implications for the intensive care unit care. Clinical Microbiology and Infection, 2009, 15, 850-857.	2.8	55
106	Risk factors for death after sepsis in patients immunosuppressed before the onset of sepsis. Scandinavian Journal of Infectious Diseases, 2009, 41, 469-479.	1.5	35
107	Mechanism of Resistance in Metronidazole. , 2009, , 223-227.		18
108	Repeated enzyme immunoassays have limited utility in diagnosing Clostridium difficile. European Journal of Clinical Microbiology and Infectious Diseases, 2008, 27, 397-399.	1.3	20

#	Article	IF	CITATIONS
109	Prior Environmental Contamination Increases the Risk of Acquisition of Vancomycin-Resistant Enterococci. Clinical Infectious Diseases, 2008, 46, 678-685.	2.9	242
110	Antibiotic Exposure and Room Contamination Among Patients Colonized With Vancomycin-Resistant Enterococci. Infection Control and Hospital Epidemiology, 2008, 29, 709-715.	1.0	33
111	The Safety of Probiotics. Clinical Infectious Diseases, 2008, 46, S104-S111.	2.9	272
112	In Vitro Activities of Doripenem, a New Broad-Spectrum Carbapenem, against Recently Collected Clinical Anaerobic Isolates, with Emphasis on the <i>Bacteroides fragilis</i> Group. Antimicrobial Agents and Chemotherapy, 2008, 52, 4492-4496.	1.4	30
113	Use of Valganciclovir for Prevention and Treatment of Cytomegalovirus Disease. Clinical Infectious Diseases, 2008, 46, 28-29.	2.9	11
114	Editorial Commentary:Persistent Clinical Impact of Cytomegalovirus in Organ Transplantation. Clinical Infectious Diseases, 2008, 47, 883-884.	2.9	8
115	Destruction of Isolates from the Pittsburgh Veterans Affairs Laboratory. Clinical Infectious Diseases, 2008, 46, 1053-1059.	2.9	3
116	National Survey on the Susceptibility of Bacteroides fragilis Group: Report and Analysis of Trends in the United States from 1997 to 2004. Antimicrobial Agents and Chemotherapy, 2007, 51, 1649-1655.	1.4	153
117	Prophylaxis and treatment of cytomegalovirus disease in recipients of solid organ transplants: current approach and future challenges. Current Opinion in Infectious Diseases, 2007, 20, 419-424.	1.3	17
118	Prevention of Catheter-Related Bloodstream Infections: Looking to the Department of Veterans Affairs Health Care System for Guidance. Mayo Clinic Proceedings, 2007, 82, 665.	1.4	1
119	Prevention of Catheter-Related Bloodstream Infections: Looking to the Department of Veterans Affairs Health Care System for Guidance. Mayo Clinic Proceedings, 2007, 82, 665.	1.4	0
120	Blood stream infection after hematopoietic stem cell transplantation is associated with increased mortality. Bone Marrow Transplantation, 2007, 40, 63-70.	1.3	171
121	Daptomycin in the treatment of vancomycin-resistant Enterococcus faecium bacteremia in neutropenic patients. Journal of Infection, 2007, 54, 567-571.	1.7	82
122	Prevention of Catheter and Intravascular Device-Related Infections: A Quality-of-Care Mandate for Institutions and Physicians. Mayo Clinic Proceedings, 2006, 81, 1151-1152.	1.4	13
123	Hypogammaglobulinemia in Liver Transplant Recipients: Incidence, Timing, Risk Factors, and Outcomes. Transplantation, 2006, 81, 697-703.	0.5	62
124	Multicenter Evaluation of the In Vitro Susceptibility of Staphylococci to Vancomycin. Infectious Diseases in Clinical Practice, 2006, 14, 89-92.	0.1	0
125	The case for cytomegalovirus prophylaxis in solid organ transplantation. Reviews in Medical Virology, 2006, 16, 289-295.	3.9	64
126	Endocarditis and pericarditis complicating pneumococcal bacteraemia, with special reference to the adhesive abilities of pneumococci: results from a prospective study. Clinical Microbiology and Infection, 2006, 12, 338-344.	2.8	41

#	Article	IF	Citations
127	The potential role for iron overload and fungal infection in liver transplantation. Liver Transplantation, 2006, 12, 1731-1732.	1.3	9
128	Preventing Post–Organ Transplantation Cytomegalovirus Disease with Ganciclovir: A Metaâ€Analysis Comparing Prophylactic and Preemptive Therapies. Clinical Infectious Diseases, 2006, 43, 869-880.	2.9	140
129	The Impact of Gown-Use Requirement on Hand Hygiene Compliance. Clinical Infectious Diseases, 2006, 42, 370-376.	2.9	57
130	Transmission of Vancomycin-Resistant Enterococcus in a Neonatal Intensive Care Unit. Pediatric Infectious Disease Journal, 2005, 24, 566-567.	1.1	30
131	Impact of cytomegalovirus prophylaxis on rejection following orthotopic liver transplantation. Liver Transplantation, 2005, $11,1597-1602$.	1.3	40
132	Viral Prophylaxis in Organ Transplant Patients. ChemInform, 2005, 36, no.	0.1	0
133	Fluconazole MIC and the Fluconazole Dose/MIC Ratio Correlate with Therapeutic Response among Patients with Candidemia. Antimicrobial Agents and Chemotherapy, 2005, 49, 3171-3177.	1.4	157
134	Evaluation of the in vitro activity of NVP-LMB415 against clinical anaerobic isolates with emphasis on the Bacteroides fragilis group. Journal of Antimicrobial Chemotherapy, 2005, 55, 1024-1028.	1.3	11
135	Counterpoint: Prevention of Cytomegalovirus (CMV) Infection and CMV Disease in Recipients of Solid Organ Transplants: The Case for Prophylaxis. Clinical Infectious Diseases, 2005, 40, 709-712.	2.9	37
136	Lactobacillus GG: Bacteriology and Clinical Applications. Gastroenterology Clinics of North America, 2005, 34, 483-498.	1.0	176
137	Daptomycinâ€Resistant, Methicillinâ€ResistantStaphylococcus aureusBacteremia. Clinical Infectious Diseases, 2005, 40, 1058-1060.	2.9	234
138	The Clinical Impact of Ganciclovir Prophylaxis on the Occurrence of Bacteremia in Orthotopic Liver Transplant Recipients. Clinical Infectious Diseases, 2004, 39, 1293-1299.	2.9	65
139	Iron Storage Indices: Novel Predictors of Bacteremia in Hemodialysis Patients Initiating Intravenous Iron Therapy. Clinical Infectious Diseases, 2004, 38, 1090-1094.	2.9	93
140	Combination Antibiotic Therapy Lowers Mortality among Severely Ill Patients with Pneumococcal Bacteremia. American Journal of Respiratory and Critical Care Medicine, 2004, 170, 440-444.	2.5	421
141	In Vitro Activities of Tigecycline against the Bacteroides fragilis Group. Antimicrobial Agents and Chemotherapy, 2004, 48, 1034-1036.	1.4	64
142	Intra-abdominal infections: review of the bacteriology, antimicrobial susceptibility and the role of ertapenem in their therapy. Journal of Antimicrobial Chemotherapy, 2004, 53, ii29-ii36.	1.3	33
143	Iron storage indices and risk of bacterial infections in hemodialysis patients. Hemodialysis International, 2004, 8, 226-232.	0.4	11
144	Viral Prophylaxis in Organ Transplant Patients. Drugs, 2004, 64, 2763-2792.	4.9	91

#	Article	IF	CITATIONS
145	Cytomegalovirus Reactivation and Relapse Following Allogeneic Stem Cell Transplantation Using a Reduced Intensity Conditioning Regimen Blood, 2004, 104, 5104-5104.	0.6	0
146	Vancomycin-resistant enterococcal infections: Cause for concern?. Liver Transplantation, 2003, 9, 1227-1228.	1.3	0
147	An International Prospective Study of Pneumococcal Bacteremia: Correlation with In Vitro Resistance, Antibiotics Administered, and Clinical Outcome. Clinical Infectious Diseases, 2003, 37, 230-237.	2.9	426
148	Resource Utilization Among Patients With Sepsis Syndrome. Infection Control and Hospital Epidemiology, 2003, 24, 62-70.	1.0	22
149	Severe sepsis: variation in resource and therapeutic modality use among academic centers. Critical Care, 2003, 7, R24.	2.5	53
150	Randomized Comparison of Oral Valacyclovir and Intravenous Ganciclovir for Prevention of Cytomegalovirus Disease after Allogeneic Bone Marrow Transplantation. Clinical Infectious Diseases, 2003, 36, 749-758.	2.9	111
151	Emergence of fluoroquinolone resistance among Bacteroides species. Journal of Antimicrobial Chemotherapy, 2003, 52, 208-213.	1.3	71
152	Reduced Acquisition of Vancomycinâ€Resistant Enterococci: Gown Effect or Confounding?. Clinical Infectious Diseases, 2003, 36, 535-536.	2.9	2
153	Role of Environmental Contamination as a Risk Factor for Acquisition of Vancomycin-Resistant Enterococci in Patients Treated in a Medical Intensive Care Unit. Archives of Internal Medicine, 2003, 163, 1905.	4.3	187
154	Relationship of pulmonary artery catheter use to mortality and resource utilization in patients with severe sepsis*. Critical Care Medicine, 2003, 31, 2734-2741.	0.4	108
155	Shifting Patterns in the Epidemiology of Nosocomial Candida Infections*. Chest, 2003, 123, 500S-503S.	0.4	123
156	Real-time antifungal susceptibility screening aids management of invasive yeast infections in immunocompromised patients. Journal of Antimicrobial Chemotherapy, 2002, 49, 415-419.	1.3	25
157	GB Virus C and Mortality from HIV Infection. New England Journal of Medicine, 2002, 346, 377-379.	13.9	20
158	National Survey on the Susceptibility ofBacteroides fragilisGroup: Report and Analysis of Trends for 1997–2000. Clinical Infectious Diseases, 2002, 35, S126-S134.	2.9	94
159	In Vitro Activities of Newer Quinolones against Bacteroides Group Organisms. Antimicrobial Agents and Chemotherapy, 2002, 46, 3276-3279.	1.4	41
160	Attributable Mortality of Stenotrophomonas maltophilia Bacteremia. Clinical Infectious Diseases, 2002, 34, 1653-1656.	2.9	111
161	Clinical utility of blood cultures drawn from central venous or arterial catheters in critically ill surgical patients. Critical Care Medicine, 2002, 30, 7-13.	0.4	69
162	Association between the Presence of Enterococcal Virulence Factors Gelatinase, Hemolysin, and Enterococcal Surface Protein and Mortality among Patients with Bacteremia Due toEnterococcus faecalis. Clinical Infectious Diseases, 2002, 35, 570-575.	2.9	108

#	Article	IF	Citations
163	Use of combination cytomegalovirus immune globulin plus ganciclovir for prophylaxis in CMV-seronegative liver transplant recipients of a CMV-seropositive donor organ: a multicenter, open-label study. Transplantation Proceedings, 2001, 33, 2571-2575.	0.3	35
164	Historical overview of the use of cytomegalovirus hyperimmune globulin in organ transplantation. Transplant Infectious Disease, 2001, 3, 6-13.	0.7	41
165	Posttransplant Microbiological Surveillance. Clinical Infectious Diseases, 2001, 33, S22-S25.	2.9	28
166	Determinants of Vancomycin Resistance and Mortality Rates in Enterococcal Bacteremia: A Prospective Multicenter Study. Annals of Internal Medicine, 2001, 135, 484.	2.0	273
167	Prevention of Cytomegalovirus Disease in Recipients of Solid-Organ Transplants. Clinical Infectious Diseases, 2001, 32, 596-603.	2.9	115
168	Association of Human Herpesvirus 6 Reactivation with Severe Cytomegalovirusâ€Associated Disease in Orthotopic Liver Transplant Recipients. Clinical Infectious Diseases, 2001, 33, 1358-1362.	2.9	65
169	Increasing Mortality Due to End-Stage Liver Disease in Patients with Human Immunodeficiency Virus Infection. Clinical Infectious Diseases, 2001, 32, 492-497.	2.9	943
170	Epidemiology of Infections after Solidâ€Organ Transplantation. Clinical Infectious Diseases, 2001, 33, S5-S8.	2.9	94
171	Cytomegalovirus immune globulin after liver transplantation: a cost-effectiveness analysis 1. Clinical Transplantation, 2000, 14, 19-27.	0.8	16
172	Comparative In Vitro Activities of Daptomycin and Vancomycin against Resistant Gram-Positive Pathogens. Antimicrobial Agents and Chemotherapy, 2000, 44, 3447-3450.	1.4	97
173	Comparative In Vitro Activities of Clinafloxacin and Trovafloxacin against 1,000 Isolates of Bacteroides fragilis Group: Effect of the Medium on Test Results. Antimicrobial Agents and Chemotherapy, 2000, 44, 1710-1712.	1.4	14
174	Antimicrobial Resistance and Clinical Outcome of Bacteroides Bacteremia: Findings of a Multicenter Prospective Observational Trial. Clinical Infectious Diseases, 2000, 30, 870-876.	2.9	196
175	Varicella zoster virus infections following allogeneic bone marrow transplantation: Frequency, risk factors, and clinical outcome. Biology of Blood and Marrow Transplantation, 2000, 6, 44-49.	2.0	220
176	Blood Cultures Drawn from Indwelling Central Venous Catheters. Annals of Internal Medicine, 2000, 132, 922.	2.0	0
177	Clinical Utility of Blood Cultures Drawn from Indwelling Central Venous Catheters in Hospitalized Patients with Cancer. Annals of Internal Medicine, 1999, 131, 641.	2.0	161
178	OUTCOME OF TRANSPLANTATION OF ORGANS PROCURED FROM BACTEREMIC DONORS1. Transplantation, 1999, 68, 1107-1111.	0.5	157
179	Utility of Serial Rectal Swab Cultures for Detection of Ceftazidime- and Imipenem-Resistant Gram-Negative Bacilli from Patients in the Intensive Care Unit. European Journal of Clinical Microbiology and Infectious Diseases, 1998, 17, 727-730.	1.3	7
180	Antiviral Immunotherapy. BioDrugs, 1998, 9, 487-507.	2.2	15

#	Article	IF	Citations
181	Late Incidence of Cancer After Metronidazole Use: A Matched Metronidazole User/Nonuser Study. Clinical Infectious Diseases, 1998, 26, 384-388.	2.9	53
182	Infective Endocarditis in Solid Organ Transplant Recipients. Clinical Infectious Diseases, 1998, 26, 689-694.	2.9	103
183	Human Herpesvirus 6 Reactivation Is Associated with Cytomegalovirus Infection and Syndromes in Kidney Transplant Recipients at Risk for Primary Cytomegalovirus Infection. Journal of Infectious Diseases, 1998, 178, 1783-1786.	1.9	130
184	Epidemiology of Sepsis Syndrome in 8 Academic Medical Centers. Survey of Anesthesiology, 1998, 42, 196.	0.1	11
185	ORGAN DONOR SCREENING FOR INFECTIOUS DISEASES. Transplantation, 1998, 65, 603-610.	0.5	81
186	SIGNIFICANCE OF CYTOMEGALOVIRUS FOR LONG-TERM SURVIVAL AFTER ORTHOTOPIC LIVER TRANSPLANTATION. Transplantation, 1998, 66, 1020-1028.	0.5	66
187	Clinical and Epidemiological Predictors of Recurrent Cytomegalovirus Disease in Orthotopic Liver Transplant Recipients. Clinical Infectious Diseases, 1997, 25, 314-317.	2.9	44
188	Surveillance Cultures of Blood, Urine, and Throat Specimens Are Not Valuable for Predicting Cytomegalovirus Disease in Liver Transplant Recipients. Clinical Infectious Diseases, 1997, 24, 824-829.	2.9	26
189	The Independent Role of Cytomegalovirus as a Risk Factor for Invasive Fungal Disease in Orthotopic Liver Transplant Recipients. American Journal of Medicine, 1997, 103, 106-113.	0.6	294
190	Predicting Clostridium difficile Stool Cytotoxin Results in Hospitalized Patients with Diarrhea. Journal of General Internal Medicine, 1997, 12, 57-62.	1.3	14
191	Predicting Clostridium difficile Stool Cytotoxin Results in Hospitalized Patients with Diarrhea. Journal of General Internal Medicine, 1997, 12, 57-62.	1.3	18
192	CYTOMEGALOVIRUS DISEASE IS ASSOCIATED WITH INCREASED COST AND HOSPITAL LENGTH OF STAY AMONG ORTHOTOPIC LIVER TRANSPLANT RECIPIENTS1. Transplantation, 1997, 63, 1595-1601.	0.5	65
193	The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. American Journal of Medicine, 1996, 100, 617-623.	0.6	720
194	ANALYSIS OF THE IN VITRO ACTIVITY OF TROVAFLOXACIN (CP-99,219) AGAINST BACTEROIDES SPECIES. Infectious Diseases in Clinical Practice, 1996, 5, S96-S100.	0.1	8
195	Risk factors leading to clinical failure in the treatment of intra-abdominal or skin/soft tissue infections. European Journal of Clinical Microbiology and Infectious Diseases, 1996, 15, 913-921.	1.3	84
196	Analysis of Trends in Antimicrobial Resistance Patterns Among Clinical Isolates of Bacteroides fragilis Group Species from 1990 to 1994. Clinical Infectious Diseases, 1996, 23, S54-S65.	2.9	51
197	PAECILOMYCES LILACINUS SINUSITIS IN A BONE MARROW TRANSPLANT RECIPIENT. Infectious Diseases in Clinical Practice, 1996, 5, 311-314.	0.1	0
198	CYTOMEGALOVIRUS PROPHYLAXIS IN SOLID ORGAN TRANSPLANT RECIPIENTS. Transplantation, 1996, 61, 1279-1289.	0.5	181

#	Article	IF	Citations
199	INCIDENCE AND PREDICTORS OF CYTOMEGALOVIRUS PNEUMONIA IN ORTHOTOPIC LIVER TRANSPLANT RECIPIENTS 1. Transplantation, 1996, 61, 1716-1720.	0.5	29
200	Use of cytomegalovirus immunoglobulin in multiply transfused premature neonates. Pediatric Infectious Disease Journal, 1995, 14, 34-40.	1.1	43
201	Spectrum and Significance of Bacteremia Due to Moraxella catarrhalis. Clinical Infectious Diseases, 1995, 21, 390-397.	2.9	64
202	Aspergillus fumigatus Infection of a Biloma. Clinical Infectious Diseases, 1995, 20, 1427-1428.	2.9	6
203	Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study. Archives of Internal Medicine, 1995, 155, 2429-2435.	4.3	85
204	CYTOMEGALOVIRUS INFECTION IN ORGAN TRANSPLANT RECIPIENTS. Infectious Disease Clinics of North America, 1995, 9, 863-877.	1.9	63
205	New Developments in Cytomegalovirus Prevention and Management. American Journal of Kidney Diseases, 1993, 21, 217-228.	2.1	33
206	Cytomegalovirus Immune Globulin Prophylaxis in Liver Transplantation. Annals of Internal Medicine, 1993, 119, 984.	2.0	203
207	INFLUENZA VIRUS VACCINE 1993–1994 (ADAPTED WITH MINOR MODIFICATION FROM MMWR). Infectious Diseases in Clinical Practice, 1993, 2, 450-451.	0.1	0
208	CYTOMEGALOVIRUS HYPERIMMUNE GLOBULIN. Pediatric Infectious Disease Journal, 1992, 11, 777.	1.1	0
209	WHICH RENAL TRANSPLANT PATIENTS SHOULD RECEIVE CYTOMEGALOVIRUS IMMUNE GLOBULIN?. Transplantation, 1991, 52, 259-265.	0.5	39
210	Capnocytophaga infection involving a portal-systemic vascular shunt. Digestive Diseases and Sciences, 1990, 35, 909-911.	1.1	2
211	Nosocomial Sepsis Associated with Interleukin-2. Annals of Internal Medicine, 1990, 112, 102.	2.0	87
212	Cytomegalovirus Immunoglobulins in the Prevention and Treatment of Cytomegalovirus Disease. Clinical Infectious Diseases, 1990, 12, S839-S848.	2.9	68
213	The antimicrobial susceptibility patterns of the Barteroides fragilis group in the United States, 1987. Journal of Antimicrobial Chemotherapy, 1990, 25, 1011-1019.	1.3	56
214	An Outbreak of Hepatitis A among Cancer Patients Treated with Interleukin-2 and Lymphokine-Activated Killer Cells. Journal of Infectious Diseases, 1990, 161, 647-652.	1.9	36
215	Cytomegalovirus infection in solid organ transplantation: Prospects for prevention. Transplantation Reviews, 1990, 4, 59-67.	1.2	6
216	Nosocomial Branhamella catarrhalis in a paediatric intensive care unit: Risk factors for disease. Journal of Hospital Infection, 1989, 13, 299-307.	1.4	38

#	Article	IF	Citations
217	Ganciclovir for Treatment of Renal Transplant-Associated Primary Cytomegalovirus Pneumonia. Journal of Infectious Diseases, 1988, 157, 187-188.	1.9	68
218	Ganciclovir Therapy for Cytomegalovirus Disease Associated with Renal Transplants. Clinical Infectious Diseases, 1988, 10, S554-S562.	2.9	45
219	Prevention of Nosocomial Transmission of Respiratory Syncytial Virus in a Newborn Nursery. Infection Control and Hospital Epidemiology, 1988, 9, 105-108.	1.0	44
220	Prevention of Nosocomial Transmission of Respiratory Syncytial Virus in a Newborn Nursery. Infection Control and Hospital Epidemiology, 1988, 9, 105-108.	1.0	36
221	Use of Cytomegalovirus Immune Globulin to Prevent Cytomegalovirus Disease in Renal-Transplant Recipients. New England Journal of Medicine, 1987, 317, 1049-1054.	13.9	571
222	Intravenous Tubing Containing Burettes Can Be Safely Changed at 72 Hour Intervals. Infection Control, 1987, 8, 113-116.	0.5	67
223	Clinical importance of cefoxitin-resistant Bacteroides fragilis isolates. Diagnostic Microbiology and Infectious Disease, 1987, 7, 119-126.	0.8	14
224	Historical perspective of lyme disease. Zentralblatt Fur Bakteriologie, Mikrobiologie, Und Hygiene Series A, Medical Microbiology, Infectious Diseases, Virology, Parasitology, 1986, 263, 3-6.	0.5	4
225	Borrelia burgdorferi in Joint Fluid in Chronic Lyme Arthritis. Annals of Internal Medicine, 1986, 104, 798.	2.0	161
226	Hepatitis in Pregnancy. New England Journal of Medicine, 1985, 313, 1398-1401.	13.9	76
227	Capnocytophaga Species: Infections in Nonimmunocompromised and Immunocompromised Hosts. Journal of Infectious Diseases, 1985, 151, 140-147.	1.9	137
228	Changing Intravenous Tubing Containing Burettes-Reply. JAMA - Journal of the American Medical Association, 1985, 253, 42.	3.8	1
229	Absence of antibodies to HTLV-III in health workers after hepatitis B vaccination. JAMA - Journal of the American Medical Association, 1985, 254, 1064-1066.	3.8	9
230	A MULTIVARIATE ANALYSIS OF RISK FACTORS FOR HEPATITIS B VIRUS INFECTION AMONG HOSPITAL EMPLOYEES SCREENED FOR VACCINATION1. American Journal of Epidemiology, 1984, 120, 684-693.	1.6	37
231	Ocular and pericardial involvement in Legionnaires' disease. American Journal of Medicine, 1984, 77, 1105-1107.	0.6	20
232	Hemophilus aphrophilus osteomyelitis. American Journal of Medicine, 1984, 76, 159-161.	0.6	19
233	A simultaneous outbreak of respiratory syncytial virus and parainfluenza virus type 3 in a newborn nursery. Journal of Pediatrics, 1984, 104, 680-684.	0.9	106
234	A PILOT TRIAL OF A NOVEL CYTOMEGALOVIRUS IMMUNE GLOBULIN IN RENAL TRANSPLANT RECIPIENTS. Transplantation, 1984, 38, 553-556.	0.5	32

#	Article	IF	Citations
235	Intravenous tubing with burettes can be safely changed at 48-hour intervals. JAMA - Journal of the American Medical Association, 1984, 251, 2112-2115.	3.8	24
236	BACTERIA IN TOTAL PARENTERAL NUTRITION CATHETERS. Lancet, The, 1983, 321, 940-941.	6.3	2
237	Pneumocystis carinii and Cytomegalovirus Pneumonia in a Previously Healthy Adult1,2. The American Review of Respiratory Disease, 1982, 125, 601-603.	2.9	10
238	Investigation of an Epidemic of Multi-Drug Resistant Pseudomonas aeruginosa. Infection Control, 1982, 3, 456-460.	0.5	9
239	Total parenteral nutrition-related infections. American Journal of Medicine, 1982, 73, 695-699.	0.6	186
240	PREDICTIVE VALUE OF SURVEILLANCE SKIN CULTURES IN TOTAL-PARENTERAL-NUTRITION-RELATED INFECTION. Lancet, The, 1982, 320, 1385-1388.	6.3	176
241	Infectious Mononucleosis in an Adult Progressing to Fatal Immunoblastic Lymphoma. Annals of Internal Medicine, 1982, 96, 737.	2.0	37
242	Use of IgM-Hepatitis A Antibody Testing. JAMA - Journal of the American Medical Association, 1981, 245, 827.	3.8	16
243	Use of IgM-hepatitis A antibody testing. Investigating a common-source, food borne outbreak. JAMA - Journal of the American Medical Association, 1981, 245, 827-830.	3.8	25
244	Bacteroides bivius and Bacteroides disiens in obstetrical patients: clinical findings and antimicrobial susceptibilities. Journal of Antimicrobial Chemotherapy, 1980, 6, 519-525.	1.3	40
245	Plasmid-Mediated, Transferable Resistance to Clindamycin and Erythromycin in Bacteroides fragilis. Journal of Infectious Diseases, 1979, 139, 83-88.	1.9	117
246	Antiviral Agents. Drugs, 1979, 18, 354-376.	4.9	20
247	Sputum. Archives of Internal Medicine, 1978, 138, 1778.	4.3	3
248	Sputum: a diagnostic pitfall in alcoholics. Archives of Internal Medicine, 1978, 138, 1778-1779.	4.3	3
249	PSEUDOBACTEREMIA: FALSEPOSITIVE BLOOD CULTURES FROM MIST TENT CONTAMINATION. American Journal of Epidemiology, 1977, 106, 154-159.	1.6	31
250	An epidemic of oligoarticular arthritis in children and adults in three connecticut communities. Arthritis and Rheumatism, 1977, 20, 7-17.	6.7	1,206
251	HEMODIALYSIS-ASSOCIATED HEPATITIS: REPORT OF AN EPIDEMIC WITH FURTHER EVIDENCE ON MECHANISMS OF TRANSMISSION. American Journal of Epidemiology, 1976, 104, 563-570.	1.6	56
252	Transmission of Hepatitis B Associated with Hemodialysis: Role of Malfunction (Blood Leaks) in Dialysis Machines. Journal of Infectious Diseases, 1976, 134, 562-570.	1.9	29

#	Article	IF	CITATIONS
253	Hepatitis B Infection From Medical Personnel. JAMA - Journal of the American Medical Association, 1976, 236, 1009.	3.8	2
254	Nosocomial Viral Hepatitis B. Annals of Internal Medicine, 1976, 85, 573.	2.0	66
255	Prevention of Nosocomial Viral Hepatitis, Type B (Hepatitis B). Annals of Internal Medicine, 1975, 83, 838.	2.0	34
256	Thin-layer chromatography of citric acid cycle intermediates, pyruvate and lactate. Journal of Chromatography A, 1968, 36, 390-393.	1.8	10